Literature DB >> 9696814

Control of murine cytomegalovirus in the lungs: relative but not absolute immunodominance of the immediate-early 1 nonapeptide during the antiviral cytolytic T-lymphocyte response in pulmonary infiltrates.

R Holtappels1, J Podlech, G Geginat, H P Steffens, D Thomas, M J Reddehase.   

Abstract

The lungs are a major organ site of cytomegalovirus (CMV) infection, pathogenesis, and latency. Interstitial CMV pneumonia represents a critical manifestation of CMV disease, in particular in recipients of bone marrow transplantation (BMT). We have employed a murine model for studying the immune response to CMV in the lungs in the specific scenario of immune reconstitution after syngeneic BMT. Control of pulmonary infection was associated with a vigorous infiltration of the lungs, which was characterized by a preferential recruitment and massive expansion of the CD8 subset of alpha/beta T cells. The infiltrate provided a microenvironment in which the CD8 T cells differentiated into mature effector cells, that is, into functionally active cytolytic T lymphocytes (CTL). This gave us the opportunity for an ex vivo testing of the antigen specificities of CTL present at a relevant organ site of viral pathogenesis. The contribution of the previously identified immediate-early 1 (IE1) nonapeptide of murine CMV was evaluated by comparison with the CD3epsilon-redirected cytolytic activity used as a measure of the overall CTL response in the lungs. The IE1 peptide was detected by pulmonary CTL, but it accounted for a minor part of the response. Interestingly, no additional viral or virus-induced antigenic peptides were detectable among naturally processed peptides derived from infected lungs, even though infected fibroblasts were recognized in a major histocompatibility complex-restricted manner. We conclude that the antiviral pulmonary immune response is a collaborative function that involves many antigenic peptides, among which the IE1 peptide is immunodominant in a relative sense.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9696814      PMCID: PMC109942     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence.

Authors:  H P Steffens; S Kurz; R Holtappels; M J Reddehase
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

Review 2.  Interference with antigen processing by viruses.

Authors:  H Hengel; U H Koszinowski
Journal:  Curr Opin Immunol       Date:  1997-08       Impact factor: 7.486

3.  IFN-gamma is a prerequisite for optimal antigen processing of viral peptides in vivo.

Authors:  G Geginat; T Ruppert; H Hengel; R Holtappels; U H Koszinowski
Journal:  J Immunol       Date:  1997-04-01       Impact factor: 5.422

4.  Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity.

Authors:  T Kataoka; N Shinohara; H Takayama; K Takaku; S Kondo; S Yonehara; K Nagai
Journal:  J Immunol       Date:  1996-05-15       Impact factor: 5.422

5.  Bone marrow failure by cytomegalovirus is associated with an in vivo deficiency in the expression of essential stromal hemopoietin genes.

Authors:  A Mayer; J Podlech; S Kurz; H P Steffens; S Maiberger; K Thalmeier; P Angele; L Dreher; M J Reddehase
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

6.  Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection.

Authors:  K Murali-Krishna; J D Altman; M Suresh; D J Sourdive; A J Zajac; J D Miller; J Slansky; R Ahmed
Journal:  Immunity       Date:  1998-02       Impact factor: 31.745

7.  The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells.

Authors:  H T Reyburn; O Mandelboim; M Valés-Gómez; D M Davis; L Pazmany; J L Strominger
Journal:  Nature       Date:  1997-04-03       Impact factor: 49.962

8.  A new look at T cells.

Authors:  A J McMichael; C A O'Callaghan
Journal:  J Exp Med       Date:  1998-05-04       Impact factor: 14.307

9.  Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes.

Authors:  A Gallimore; A Glithero; A Godkin; A C Tissot; A Plückthun; T Elliott; H Hengartner; R Zinkernagel
Journal:  J Exp Med       Date:  1998-05-04       Impact factor: 14.307

10.  Costimulation by B7 modulates specificity of cytotoxic T lymphocytes: a missing link that explains some bystander T cell activation.

Authors:  P Zheng; Y Liu
Journal:  J Exp Med       Date:  1997-11-17       Impact factor: 14.307

View more
  55 in total

1.  Random, asynchronous, and asymmetric transcriptional activity of enhancer-flanking major immediate-early genes ie1/3 and ie2 during murine cytomegalovirus latency in the lungs.

Authors:  N K Grzimek; D Dreis; S Schmalz; M J Reddehase
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

2.  Experimental preemptive immunotherapy of murine cytomegalovirus disease with CD8 T-cell lines specific for ppM83 and pM84, the two homologs of human cytomegalovirus tegument protein ppUL83 (pp65).

Authors:  R Holtappels; J Podlech; N K Grzimek; D Thomas; M F Pahl-Seibert; M J Reddehase
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  Two antigenic peptides from genes m123 and m164 of murine cytomegalovirus quantitatively dominate CD8 T-cell memory in the H-2d haplotype.

Authors:  Rafaela Holtappels; Doris Thomas; Jürgen Podlech; Matthias J Reddehase
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

4.  Enrichment of immediate-early 1 (m123/pp89) peptide-specific CD8 T cells in a pulmonary CD62L(lo) memory-effector cell pool during latent murine cytomegalovirus infection of the lungs.

Authors:  R Holtappels; M F Pahl-Seibert; D Thomas; M J Reddehase
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 5.  CD8 T-cell-based immunotherapy of cytomegalovirus infection: "proof of concept" provided by the murine model.

Authors:  Rafaela Holtappels; Verena Böhm; Jürgen Podlech; Matthias J Reddehase
Journal:  Med Microbiol Immunol       Date:  2008-03-15       Impact factor: 3.402

6.  Immune evasion proteins enhance cytomegalovirus latency in the lungs.

Authors:  Verena Böhm; Christof K Seckert; Christian O Simon; Doris Thomas; Angélique Renzaho; Dorothea Gendig; Rafaela Holtappels; Matthias J Reddehase
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

7.  Hyperexpansion of Functional Viral-Specific CD8+ T Cells in Lymphopenia-Associated MCMV Pneumonitis.

Authors:  Pali D Shah; Qiong Zhong; Elizabeth A Lendermon; Matthew R Pipeling; John F McDyer
Journal:  Viral Immunol       Date:  2015-05-18       Impact factor: 2.257

8.  Control of cytomegalovirus in bone marrow transplantation chimeras lacking the prevailing antigen-presenting molecule in recipient tissues rests primarily on recipient-derived CD8 T cells.

Authors:  M Alterio de Goss; R Holtappels; H P Steffens; J Podlech; P Angele; L Dreher; D Thomas; M J Reddehase
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

9.  Inflation and long-term maintenance of CD8 T cells responding to a latent herpesvirus depend upon establishment of latency and presence of viral antigens.

Authors:  Anna Lang; James D Brien; Janko Nikolich-Zugich
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

10.  Differential CMV-specific CD8+ effector T cell responses in the lung allograft predominate over the blood during human primary infection.

Authors:  Matthew R Pipeling; Erin E West; Christine M Osborne; Amanda B Whitlock; Lesia K Dropulic; Matthew H Willett; Michael Forman; Alexandra Valsamakis; Jonathan B Orens; David R Moller; Noah Lechtzin; Stephen A Migueles; Mark Connors; John F McDyer
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.